Xalacom
ApprovedSmall molecule
Xalacom is one of 66 small molecule programs targeting Glaucoma. It is currently in Approved.
3
Indications
12
Total Trials
0
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Alphagan
NovartisPhase 3
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Xalacom
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Azopt
NovartisPhase 3
Ocupress
AbbViePhase 3
LUMIGAN
AbbViePhase 3
Krytantek
AbbViePhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
Combigan
EEMS
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Glaucoma4 trials
Ocular Hypertension4 trials
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00383019·300 enrolled
Show 1 more trial
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00219596·240 enrolled
Intraocular Pressure1 trial
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00143208·250 enrolled
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xalacom. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details